GET THE APP

New benzimidazole-hydrazones as MAO inhibitors
..

Medicinal Chemistry

ISSN: 2161-0444

Open Access

New benzimidazole-hydrazones as MAO inhibitors


International Conference on Pharmaceutical Chemistry

September 05-07, 2016 Frankfurt, Germany

Ozgur Devrim CAN, Umide DEMIR UZKAY, Derya OSMANIYE and Begum Nurpelin SAILIK

Anadolu University, Turkey

Posters & Accepted Abstracts: Med chem

Abstract :

Monoamine oxidase inhibitors (MAOIs) are agents, which inhibit the activity of the monoamine oxidase (MAO) enzymes. These drugs possess a long history of use as medications proposed for the treatment of depression. MAOIs are especially effective in the control of atypical depression. MAO-B inhibitors are also preferred in the treatment of Parkinson�s disease. Propargyl moiety is an important pharmacophoric group which presents in the chemical structures of MAO inhibitors as selegiline and rasagiline. Hydrazone is another essential functional group in terms of MAO inhibition. Thus, in the present study some new benzimidazole compounds bearing propargyl and hydrazone side chains were synthesized. Structures of the synthesized compounds were evaluated by IR, 1H-NMR, 13C-NMR and Mass spectroscopic methods. Effects of the synthesized compounds on MAO enzymes were observed by using kynuramine based in-vitro fluorimetric method. Activity studies revealed that synthesized compounds have more selectivety against MAO-B enzyme.

Biography :

Özgür Devrim CAN has completed his PhD from Anadolu University. She received Associate Professor Degree in 2013. She has published more than 30 papers in reputed journals. Central Nervous System related drugs constitute her main research area.

Email: ozgurdt@anadolu.edu.tr

Google Scholar citation report
Citations: 6627

Medicinal Chemistry received 6627 citations as per Google Scholar report

Medicinal Chemistry peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward